Company Filing History:

16 out of 940

Fujisawa Pharmaceutical Company, Ltd.

Years Active: 1983-2008

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7317107 - Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity (2008-01-08),

2. 7166598 - Piperazine derivatives (2007-01-23),

3. 6927230 - Triazole derivatives (2005-08-09),

4. 6924278 - Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists (2005-08-02),

5. 6087357 - Piperazine derivatives as tachykinin antagonists (2000-07-11),

6. 5939413 - Piperazine derivatives (1999-08-17),

7. 5883098 - Piperazine derivatives (1999-03-16),

8. 5670533 - Pyrazole derivatives, processes for preparation thereof and (1997-09-23),

9. 5670505 - Piperazine derivatives (1997-09-23),

10. 5571810 - Thiophene derivatives (1996-11-05),

11. 5550147 - Pyrazole derivatives, processes for preparation thereof and (1996-08-27),

12. 5134142 - Pyrazole derivatives, and pharmaceutical composition comprising the same (1992-07-28),

13. 5034417 - New alkanesulfonanilide derivatives, processes for preparation thereof (1991-07-23),

14. 4866091 - Alkanesulfonanilide derivatives, processes for preparation thereof and (1989-09-12),

15. 4738967 - Imidazoisoquinoline compounds useful as anti-ulcerative agents (1988-04-19),

Title: The Innovative Contributions of Nobukiyo Konishi

Introduction: Nobukiyo Konishi, an accomplished inventor from Nagaokakyo, Japan, has made significant contributions to the field of pharmaceuticals, holding a remarkable total of 18 patents. His inventive work focuses on compounds with therapeutic applications, particularly in the treatment of diseases mediated by adenosine and tachykinin.

Latest Patents: Among Konishi's most recent patents is the development of imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity. These compounds are characterized by specific structural formulas, featuring variations in aryl, heteroaryl, alkyl groups, and other components. They have shown promise in preventing and treating ailments where adenosine plays a critical role. Additionally, he has patented piperazine derivatives, which are designed to treat or prevent tachykinin-mediated diseases in humans and animals. This patent covers the compounds' structure, preparation processes, and potential pharmaceutical compositions.

Career Highlights: Throughout his career, Nobukiyo Konishi has worked with notable pharmaceutical companies, including Fujisawa Pharmaceutical Company, Ltd. and Astellas Pharma GmbH. His extensive background in these organizations has contributed to his innovative edge in pharmaceutical development.

Collaborations: Konishi has collaborated with distinguished colleagues such as Masaaki Matsuo and Kiyoshi Tsuji. These partnerships have undoubtedly enhanced his research and invention process, leading to the creation of valuable therapeutics.

Conclusion: Nobukiyo Konishi stands out as a prominent figure in the field of pharmaceutical innovation. His dedication to developing novel compounds with medicinal properties exemplifies the impact that inventors can have on health and science. With a robust portfolio of 18 patents, his contributions continue to influence the treatment of various diseases, showcasing the importance of creative development in the medical sector.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.